CA2321189A1 - Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations - Google Patents

Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations Download PDF

Info

Publication number
CA2321189A1
CA2321189A1 CA002321189A CA2321189A CA2321189A1 CA 2321189 A1 CA2321189 A1 CA 2321189A1 CA 002321189 A CA002321189 A CA 002321189A CA 2321189 A CA2321189 A CA 2321189A CA 2321189 A1 CA2321189 A1 CA 2321189A1
Authority
CA
Canada
Prior art keywords
flk
flt
vegf
antisense
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321189A
Other languages
English (en)
Inventor
Martin G. Sirois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Cardiologie de Montreal
Original Assignee
Institut de Cardiologie de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Cardiologie de Montreal filed Critical Institut de Cardiologie de Montreal
Priority to CA002321189A priority Critical patent/CA2321189A1/fr
Publication of CA2321189A1 publication Critical patent/CA2321189A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002321189A 2000-10-13 2000-10-13 Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations Abandoned CA2321189A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002321189A CA2321189A1 (fr) 2000-10-13 2000-10-13 Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002321189A CA2321189A1 (fr) 2000-10-13 2000-10-13 Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2321189A1 true CA2321189A1 (fr) 2002-04-13

Family

ID=4167252

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321189A Abandoned CA2321189A1 (fr) 2000-10-13 2000-10-13 Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations

Country Status (1)

Country Link
CA (1) CA2321189A1 (fr)

Similar Documents

Publication Publication Date Title
US20030186920A1 (en) Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
US7235534B2 (en) Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )
JP6396387B2 (ja) 腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療
KR101877698B1 (ko) 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
KR101682735B1 (ko) 뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
JP6250930B2 (ja) トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
KR101749352B1 (ko) Ｓｉｒｔ1에 대한 천연 안티센스 전사체의 억제에 의해 ｓｉｒｔ1 관련된 질환의 치료
JP5971948B2 (ja) Ｖｅｇｆに対する天然アンチセンス転写物の抑制による血管内皮増殖因子（ｖｅｇｆ）関連疾患の治療
AU2004220525B2 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
JP6091752B2 (ja) Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
JP6066035B2 (ja) グリア細胞由来神経栄養因子（ｇｄｎｆ）関連疾病の、ｇｄｎｆに対する天然アンチセンス転写物の抑制による治療
KR101900962B1 (ko) 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
JP2002526125A (ja) 腫瘍壊死因子−α（ＴＮＦ−α）発現のアンチセンス・オリゴヌクレオチド調節
KR20090103894A (ko) 고콜레스테롤혈증을 치료하는 방법
US6001991A (en) Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
JP2002526095A (ja) 腫瘍壊死因子受容体関連因子（ｔｒａｆ）の発現のアンチセンスモジュレーション
WO2001068667A1 (fr) Arret de la proliferation de tumeurs fortement glycolitiques
CA2321189A1 (fr) Oligonucleotides anti-sens diriges vers des genes recepteurs vegf mammaliens et leurs utilisations
JP4546454B2 (ja) Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CA2471127A1 (fr) Methode anti-sens de modulation de la reponse des recepteurs d'oestrogenes (er.alpha. et/ou er.beta.)
WO2021062251A2 (fr) Ciblage de rlim pour moduler le poids corporel et l'obésité
WO2000058523A9 (fr) Agoniste du recepteur de glucocorticoides et taux de pp5 reduits
PT2336318E (pt) Modulação anti-sentido da expressão de apolipoproteína b
US20080214517A1 (en) Modulation of the Expression of Estrogen Receptors for the Prevention or Treatment of Heart Disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead